Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Equity Income (2019 - 2025)

Historic Equity Income for Ultragenyx Pharmaceutical (RARE) over the last 7 years, with Q3 2025 value amounting to $678000.0.

  • Ultragenyx Pharmaceutical's Equity Income changed 0.0% to $678000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 14461.67%. This contributed to the annual value of -$1.1 million for FY2024, which is 38085.64% down from last year.
  • Ultragenyx Pharmaceutical's Equity Income amounted to $678000.0 in Q3 2025, which was down 0.0% from -$9000.0 recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Equity Income's 5-year high stood at $25.7 million during Q3 2021, with a 5-year trough of -$31.0 million in Q2 2021.
  • Moreover, its 5-year median value for Equity Income was -$334000.0 (2023), whereas its average is -$3.2 million.
  • Within the past 5 years, the most significant YoY rise in Ultragenyx Pharmaceutical's Equity Income was 122155.69% (2024), while the steepest drop was 162911.88% (2024).
  • Ultragenyx Pharmaceutical's Equity Income (Quarter) stood at -$16.1 million in 2021, then skyrocketed by 111.43% to $1.8 million in 2022, then grew by 2.66% to $1.9 million in 2023, then plummeted by 181.95% to -$1.5 million in 2024, then soared by 143.8% to $678000.0 in 2025.
  • Its last three reported values are $678000.0 in Q3 2025, -$9000.0 for Q2 2025, and -$157000.0 during Q1 2025.